CNS Pharmaceuticals, Inc.
CNSP
$5.78
-$0.16-2.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.72% | -49.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.73% | -16.89% | |||
| Operating Income | 45.73% | 16.89% | |||
| Income Before Tax | 47.58% | 17.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.58% | 17.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.58% | 17.11% | |||
| EBIT | 45.73% | 16.89% | |||
| EBITDA | 45.93% | 16.91% | |||
| EPS Basic | 94.82% | 24.75% | |||
| Normalized Basic EPS | 94.82% | 24.75% | |||
| EPS Diluted | 94.80% | 24.75% | |||
| Normalized Diluted EPS | 94.82% | 24.75% | |||
| Average Basic Shares Outstanding | 911.27% | 10.17% | |||
| Average Diluted Shares Outstanding | 911.27% | 10.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||